Background: Pharmacogenomic (PGx) testing is a potential tool to inform clinicians’ treatment decisions for patients with Major Depressive Disorder (MDD). However, there is mixed evidence...
Background: Here we present the first prospective, large-scale, patient- and rater-blind, randomized controlled trial evaluating the utility of combinatorial pharmacogenomic (PGx) testing...